Corbus Pharmaceuticals Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
On August 29, 2024, John Jenkins M.D., a member of theboard of directors, adopteda Rule 10b5-1 plan providing for the sale of up to 5,436 shares of the Company’s common stock. Pursuant to this plan, Dr. Jenkins may sell shares of common stock beginning on November 30, 2024, subject to the terms of the agreement, and the plan terminateson November 29, 2025. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
No other directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the third quarter of 2024.
-30-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.